Skip to content
OpenCapital
Get started

Idexx Laboratories IDXX Rapid assay products — Total Revenue

Other product segments

IDEXX VetLab consumables
$412.58M+19.7%
Reference laboratory diagnostic and consulting services
$386.18M+12.1%
Recurring revenue
$73.54M+11.8%
CAG Diagnostics capital - instruments
$42.45M+32.7%
CAG Diagnostics services and accessories
$36.61M+10.8%
Systems and hardware
$17.75M+12.5%

Similar metrics at other companies

Zoetis logo
ZTSAnimal health diagnostics — Revenue
$117M+12.5%
Zoetis logo
ZTSDogs and Cats — Revenue
$1.44B-2.3%
GeneDx Holdings logo
WGSDiagnostic Test — Total Revenue
$101.3M+18.1%
Veracyte logo
VCYTTesting revenue — Total Revenue
$135.09M+25.9%
Zoetis logo
ZTSOther Non Pharmaceuticals — Revenue
$66M-7.0%
Natera, Inc. logo
NTRAProduct revenues — Total revenues
$693.87M+38.8%

Other financials

Income statement

See full
Revenue$1.1B+14.3%
Gross profit$722.7M+15.9%
Operating income$362.6M+14.5%
Net income$278.4M+14.7%
EPS (diluted)$3.47+17.2%

Balance sheet

See full
Cash & equivalents$200.5M+22.3%
Total debt$575.5M-22.2%
Total equity$1.6B+7.5%
Total assets$3.4B+5.3%

Cash flow

See full
Operating cash flow$266.2M+11.9%
CapEx$32.0M+6.5%
Free cash flow$234.3M+12.7%

Valuation

See full
Market cap$43.5B+2.0%
Enterprise value$43.88B+1.7%
P/E39.7×-3.6×
P/S9.8×-0.8×

Profitability

See full
Gross margin62.1%+0.8pp
Operating margin31.6%+2.5pp
Net margin24.6%+1.9pp
FCF margin24.4%+2.8pp

Returns & leverage

See full
Return on equity72.9%+13.6pp
Debt / equity0.4×-0.1×
Current ratio1.1×0.0×

Where this comes from

Reported directly by Idexx Laboratories in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Idexx Laboratories’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Idexx Laboratories's rapid assay products — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Idexx Laboratories's rapid assay products — total revenue?
Idexx Laboratories (IDXX) reported rapid assay products — total revenue of $84.94M in Q1 2026.
How has Idexx Laboratories's rapid assay products — total revenue changed year-over-year?
Idexx Laboratories's rapid assay products — total revenue increased by 1.1% year-over-year, from $84.03M to $84.94M.
What is the long-term trend for Idexx Laboratories's rapid assay products — total revenue?
Over 4 years (2021 to 2025), Idexx Laboratories's rapid assay products — total revenue has grown at a 4.1% compound annual growth rate (CAGR), from $296.85M to $348.95M.
What does rapid assay products — total revenue mean?
This metric represents the total revenue generated from the sale of point-of-care diagnostic test kits designed for rapid, in-clinic use by veterinary professionals. These single-use assays allow for immediate disease detection and health monitoring during patient visits, serving as a critical recurring revenue stream for the company. The performance of this segment reflects the volume of diagnostic testing performed directly within veterinary practices.